down arrow

Athersys, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04744L2051
USD
0.00
0.00 (0.00%)

Dec 02

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.000.00
Valuation
Technical
Day's Volume

CASH

99

Shareholding (Dec 2023)

FII

0.48%

Held by 28 FIIs

DII

96.95%

Held by 3 DIIs

Promoter

0.00%

How big is Athersys, Inc.?

22-Jun-2025

As of Jun 18, Athersys, Inc. has a market capitalization of 0.00, classifying it as a Micro Cap company, with recent net sales of 0.08 million and a net profit of -37.50 million. The company reported shareholder's funds of -23.85 million and total assets of 27.73 million as of Dec 22.

Market Cap: As of Jun 18, Athersys, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Athersys, Inc. reported net sales of 0.08 million and a net profit of -37.50 million.<BR><BR>Balance Sheet Snapshot: As of Dec 22, the company reported shareholder's funds of -23.85 million and total assets of 27.73 million.

Read More

Who are in the management team of Athersys, Inc.?

22-Jun-2025

As of March 2022, Athersys, Inc.'s management team includes Dr. Gil Van Bokkelen (Chairman and CEO), Dr. John Harrington (Executive VP and Chief Scientific Officer), and several directors: Dr. Hardy Kagimoto, Ms. Katherine Kalin, Mr. Baiju Shah, Ms. Jane Wasman, and Dr. Ismail Kola (Independent Director). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Athersys, Inc. includes the following individuals:<BR><BR>- Dr. Gil Van Bokkelen, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Dr. John Harrington, who is the Executive Vice President, Chief Scientific Officer, and a Director.<BR>- Dr. Hardy Kagimoto, who is a Director.<BR>- Ms. Katherine Kalin, who is also a Director.<BR>- Mr. Baiju Shah, who serves as a Director.<BR>- Ms. Jane Wasman, who is a Director.<BR>- Dr. Ismail Kola, who is an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Athersys, Inc. overvalued or undervalued?

25-Jun-2025

As of August 16, 2023, Athersys, Inc. is considered overvalued and in a precarious financial situation, with a P/E ratio of 0.00 and negative enterprise value metrics, reflecting a 100% stock decline over the past year compared to a 10.26% return for the S&P 500.

As of 16 August 2023, Athersys, Inc. has moved from a grade of risky to does not qualify, indicating significant concerns regarding its valuation. The company is currently assessed as overvalued given its financial ratios, including a P/E ratio of 0.00 and an EV to EBITDA of -0.43, which suggest a lack of profitability and negative enterprise value metrics. Furthermore, the ROE stands at an extraordinarily high 118.05%, but this is misleading due to negative capital employed, highlighting the company's precarious financial situation.<BR><BR>In comparison to its peers, such as Frequency Therapeutics, Inc. with a P/E of -1.3504 and Landos Biopharma, Inc. with a P/E of -2.9258, Athersys does not present a compelling investment case. The overall peer group reflects a challenging environment, with many companies also classified as not qualifying or risky. Given these factors, Athersys appears to be overvalued, especially considering its drastic stock performance, which has seen a 100% decline over the past year compared to a 10.26% return for the S&P 500.

Read More

Is Athersys, Inc. technically bullish or bearish?

20-Sep-2025

As of October 16, 2023, Athersys, Inc. shows a mildly bearish trend with mixed technical signals, including mildly bullish weekly and monthly MACD and RSI indicators, but daily moving averages indicate a bearish stance.

As of 16 October 2023, the technical trend for Athersys, Inc. has changed from bearish to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly MACD is also mildly bullish and the RSI is bullish. However, the daily moving averages indicate a mildly bearish stance. The Bollinger Bands are showing a sideways trend for both weekly and monthly periods, and there is no discernible trend according to Dow Theory and OBV. There is no available return data to compare the company's performance against the S&P 500. Overall, the current technical stance is mildly bearish, with mixed signals across different time frames.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.48

stock-summary
Return on Equity

118.05%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
(Quarterly Results - Sep 2023)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
-100.0%
0%
-100.0%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Athersys, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Athersys, Inc. technically bullish or bearish?

As of 16 October 2023, the technical trend for Athersys, Inc. has changed from bearish to mildly bearish. The weekly MACD and KST indicators are mildly bullish, while the monthly MACD is also mildly bullish and the RSI is bullish. However, the daily moving averages indicate a mildly bearish stance. The Bollinger Bands are showing a sideways trend for both weekly and monthly periods, and there is no discernible trend according to Dow Theory and OBV. There is no available return data to compare the company's performance against the S&P 500. Overall, the current technical stance is mildly bearish, with mixed signals across different time frames....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-68.03%
EBIT Growth (5y)
-31.57%
EBIT to Interest (avg)
-55.74
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
0.52
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
7.84%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
-0.42
EV to EBITDA
-0.43
EV to Capital Employed
-0.93
EV to Sales
17.56
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
118.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 19 Schemes (2.58%)

Foreign Institutions

Held by 28 Foreign Institutions (0.48%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is 0.00% vs 0.00% in Jun 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is 70.54% vs -65.38% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.50",
          "val2": "-12.90",
          "chgp": "49.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.40",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.50",
          "val2": "2.00",
          "chgp": "75.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.80",
          "val2": "-12.90",
          "chgp": "70.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-265,061.20%",
          "chgp": "26,506.12%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is -3.64% vs 292.86% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is 16.67% vs -10.41% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.30",
          "val2": "5.50",
          "chgp": "-3.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-75.60",
          "val2": "-85.40",
          "chgp": "11.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.70",
          "val2": "-0.50",
          "chgp": "840.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-72.50",
          "val2": "-87.00",
          "chgp": "16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-14,367.90%",
          "val2": "-15,697.90%",
          "chgp": "133.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQstock-summary
Sep'23
Jun'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.50
-12.90
49.61%
Interest
0.20
0.40
-50.00%
Exceptional Items
3.50
2.00
75.00%
Consolidate Net Profit
-3.80
-12.90
70.54%
Operating Profit Margin (Excl OI)
0.00%
-265,061.20%
26,506.12%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Sep 2023 is 0.00% vs 0.00% in Jun 2023

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2023 is 70.54% vs -65.38% in Jun 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
5.30
5.50
-3.64%
Operating Profit (PBDIT) excl Other Income
-75.60
-85.40
11.48%
Interest
0.00
0.00
Exceptional Items
3.70
-0.50
840.00%
Consolidate Net Profit
-72.50
-87.00
16.67%
Operating Profit Margin (Excl OI)
-14,367.90%
-15,697.90%
133.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is -3.64% vs 292.86% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is 16.67% vs -10.41% in Dec 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About Athersys, Inc. stock-summary
stock-summary
Athersys, Inc.
Pharmaceuticals & Biotechnology
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Company Coordinates stock-summary
Company Details
3201 Carnegie Ave , CLEVELAND OH : 44115-2634
stock-summary
Tel: 1 216 4319900
stock-summary
http://www.athersys.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."